Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/GUFICBIO stock hub

NSE/GUFICBIO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/GUFICBIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

30.1B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/GUFICBIO

In the news

Latest news · NSE/GUFICBIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 24.9P50 32.4P75 45.7

Trailing P/E60.1

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC8.3

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/GUFICBIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

194

Groups with data

Currency

INR

Showing 194 of 194 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	1,484
Employees Change	-7%
Employees Change Percent	-0.47
Enterprise value	INR 32.9B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE742B01025
Last refreshed	2026-05-10
Market cap	INR 30.1B
Price	INR 305
Price currency	INR
Rev Per Employee	6,045,869.95x
Sector	Healthcare
Sic	2834
Symbol	nse/GUFICBIO
Website	https://www.gufic.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.66%
EV Earnings	65.74x
EV/EBIT	31.88x
EV/EBITDA	25.96x
EV/Sales	3.67x
P/B ratio	4.77x
P/E ratio	60.12x
P/S ratio	3.35x
PE Ratio10 Y	37.46x
PE Ratio3 Y	44.52x
PE Ratio5 Y	36.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.5%
EBITDA Margin	13.36%
Gross margin	55.06%
Gross Profit	INR 4.9B
Gross Profit Growth	15.59%
Gross Profit Growth Q	14.75%
Gross Profit Growth3 Y	12.14%
Gross Profit Growth5 Y	22.15%
Net Income	INR 500.4M
Net Income Growth	-38.96%
Net Income Growth Q	-35.65%
Net Income Growth Years	0%
Net Income Growth3 Y	-15.13%
Net Income Growth5 Y	10.42%
Pretax Margin	7.59%
Profit Margin	5.58%
Profit Per Employee	INR 337,181
Profitable Years	20
Roa5y	10.73
Roe5y	26.05
ROIC	8.31
Roic5y	19.48

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	21.63%
Cagr15y	29.67%
Cagr1y	-15.9%
Cagr20y	15.29%
Cagr3y	13.96%
Cagr5y	15.81%
Div CAGR10	7.18%
Div CAGR3	0%
Div CAGR5	0%
EPS Growth	-38.99
EPS Growth Q	-35.75
EPS Growth Years	0
EPS Growth3 Y	-16.07
EPS Growth5 Y	4.95
Revenue Growth	10.8x
Revenue Growth Q	11.37x
Revenue Growth Quarters	5x
Revenue Growth Years	2x
Revenue Growth3 Y	9.69x
Revenue Growth5 Y	17.51x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 880.8M
Debt	INR 3.7B
Debt EBITDA	INR 2.91
Debt Equity	INR 0.58
Equity	INR 6.3B
Interest Coverage	2.91
Net Cash	INR -2.8B
Net Cash By Market Cap	INR -9.34
Net Debt EBITDA	INR 2.35
Net Debt Equity	INR 0.45
Tangible Book Value	INR 6.2B
Tangible Book Value Per Share	INR 62.4
WACC	4.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.08%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	INR 0.1
Dividend Years	18
Dividend Yield	0.03%
Ex Div Date	2025-09-22
Last Dividend	INR 0.1
Payout Frequency	Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	608.25%
1Y total return	-15.89%
200-day SMA	332.1
3Y total return	48.01%
50-day SMA	289.8
50-day SMA vs 200-day SMA	50under200
5Y total return	108.3%
All Time High	504.3
All Time High Change	-39.51%
All Time High Date	2024-11-08
All Time Low	2.55
All Time Low Change	11,860.78%
All Time Low Date	2009-03-12
ATR	11.15
Beta	-0.07
Ch YTD	-9.23
High	307
High52	407.9
High52 Date	2025-07-30
High52ch	-25.22%
Low	294.3
Low52	268
Low52 Date	2026-03-09
Low52ch	13.81%
Ma50ch	5.25%
Price vs 200-day SMA	-8.16%
RSI	57.26
RSI Monthly	46.33
RSI Weekly	44.48
Sharpe ratio	-0.56x
Sortino ratio	-0.63
Total Return	-0.05%
Tr YTD	-9.23
Tr15y	4,826.49%
Tr1m	5.66%
Tr1w	4.36%
Tr3m	-0.99%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 1B
Operating Income Growth	-18.94
Operating Income Growth Q	-13.72
Operating Income Growth3 Y	-2.9
Operating Income Growth5 Y	15.71
Operating margin	11.5

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	25,859,109%
Shares Insiders	43.31%
Shares Institutions	7%
Shares Qo Q	0.05%
Shares Yo Y	0.08%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	61,614.6x
Bv Per Share	63.02
Ch10y	604.4
Ch15y	4,665.6
Ch1m	5.66
Ch1w	4.36
Ch1y	-15.91
Ch20y	1,488.5
Ch3m	-0.99
Ch3y	47.88
Ch5y	107.9
Ch6m	-8.7
Change	1.99%
Change From Open	1.77
Close	299.1
Days Gap	0.22
Depreciation Amortization	166,540,250
Dollar Volume	131,744,750
Earnings Date	2026-05-29
EBIT	INR 1B
EBITDA	INR 1.2B
EPS	INR 4.99
F Score	2
Fiscal Year End	March
Founded	1,970
Graham Number	85.46024
Graham Upside	-71.98
Income Tax	INR 180.9M
Is Primary Listing	0
Last Earnings Date	2026-02-13
Last Report Date	2025-12-31
Lynch Fair Value	INR 52.84
Lynch Upside	-82.67
Ma150	319
Ma150ch	-4.4%
Ma20	296.1
Ma20ch	2.99%
Next Earnings Date	2026-05-29
Open	299.7
Payment Date	2025-10-29
Position In Range	84.25
Price Date	2026-05-08
Price EBITDA	INR 25.11
Ptbv Ratio	4.81
Relative Volume	10.3x
Revenue	8,972,071,000x
Tax By Revenue	2.02x
Tax Rate	26.55%
Tr20y	1,622.5%
Tr6m	-8.7%
Volume	431,950

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/GUFICBIO dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.0%

$0.10 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

0.0%

0 consecutive years of growth

Total shareholder yield

-0.1%

Next ex-dividend date: 2025-09-22

Performance

NSE/GUFICBIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/GUFICBIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+7.0%

Share of float held by funds and institutions

Insider ownership

+43.3%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.1%

Negative means the company is buying back shares.

Technical

NSE/GUFICBIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

57.3

Neutral momentum band

Price vs 200-day MA

-8.2%

50/200-day relationship not available

Beta (5Y)

-0.07

Less volatile than the market

Sharpe ratio

-0.56

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/GUFICBIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/GUFICBIO stock rating?

nse/GUFICBIO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/GUFICBIO analysis?

The full report lives at /stocks/nse/GUFICBIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/GUFICBIO?

The latest report frames nse/GUFICBIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/GUFICBIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.